Amplifica Announces First-in-Human Study Initiated
Amplifica’s AMP-303 safety and tolerability study targeting hair loss
Nature Publication Reveals Cutting-Edge Advancements in Understanding Hair Growth
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage
Amplifica Expands Pipeline for Hair Loss
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage ProteinSAN
Amplifica Completes $11.8 Million Series A Financing to Enable Clinical Development of Lead Products to Treat Androgenic Alopecia
SAN DIEGO, CA - Amplifica Holdings Group, Inc. (“Amplifica”),